Parabilis Medicines adds oncology veteran Craig Tendler to board
The clinical-stage biopharma named Craig L. Tendler, M.D., a former Johnson & Johnson oncology leader, as a new Class II director on August 22, 2026.
SEC filing
Latest
1 story
Sign inSign in1 story
The clinical-stage biopharma named Craig L. Tendler, M.D., a former Johnson & Johnson oncology leader, as a new Class II director on August 22, 2026.
SEC filing